drugset / Trial / NCT04608396

Mechanistic Evaluation of Response in TRD (MERIT)

NCT04608396

Phase 2 Completed 44 enrolled Axsome Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the relapse prevention of AXS-05 relative to placebo in subjects with treatment resistant depression (TRD). This is a randomized, double-blind, placebo-controlled study to evaluate AXS-05 compared to placebo in delaying relapse of depressive symptoms in patients with TRD who are in stable remission after treatment with AXS-05.

Timeline

Start
2020-08-13
Primary completion
2021-07-30
Completion
2021-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject AXS-05 Unknown